The Boehringer Ingelheim and Lilly Alliance Supports ACC COVID-19 Response Initiative

September 17, 2020

The American College of Cardiology’s (ACC) ongoing COVID-19 response initiative is welcoming support from the Boehringer Ingelheim and Eli Lilly and Company Alliance to continue providing real-time clinical guidance on COVID-19. The comprehensive initiative includes a robust set of activities and events implemented by ACC to help cardiologists address critical patient needs and continue to deliver high-quality care.

People with existing cardiovascular disease are at high risk of lung damage and cardiovascular complications if they contract COVID-19. This is further complicated by an increased risk of developing co-morbid conditions associated with heart disease. As the pandemic progresses, many clinicians are looking for real-time guidance on managing care for these vulnerable patients, while minimizing risk to themselves and the entire cardiovascular care team.

The ACC has increasingly focused its COVID-19 response initiative on four broad areas of critical need, including key clinical/scientific guidance, optimizing cardiovascular care and operational considerations, clinician wellness, and disparities in care. This initiative, anchored by ACC’s COVID-19 hub, provides a platform for providing education and resources around these areas that clinicians can immediately put into practice as the pandemic evolves.

“The ACC is committed to transforming cardiovascular care and improving heart health, and today, that can’t be accomplished without addressing the impact the pandemic has had on our patients,” said ACC President Athena Poppas, MD, FACC. “Through this initiative, we are supporting members to answer pressing clinical questions, develop care delivery models and update the science for the health of our practices and our patients.”

Highlights of the programs and resources offered in ACC’s COVID-19 response initiative include:

  • The Summer COVID-19 Education Series – A free weekly virtual meeting providing the health care community with actionable insights and solutions to address key clinical and operational concerns.
  • Quick Tips for Fast Thinking – A video library featuring ACC thought leaders providing structured reviews of emerging science, perspectives from the frontline, and guidance on non-clinical issues and sharing best practices.
  • “Cardiology care teams need support in navigating the unique challenges brought on by COVID-19 to ensure that this high-risk patient community continues to receive the best possible care, guided by the latest science and recommendations,” said Mohamed Eid, MD, MPH, MHA, vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. “The Boehringer Ingelheim and Lilly Alliance is proud to partner with the ACC to deliver real-time education to ensure the continuity of high-quality care to people with cardiovascular disease.”

    To access the ACC’s comprehensive tools and resources for clinicians and patients, visit the ACC’s COVID-19 Hub at www.acc.org/COVID19.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version